260 related articles for article (PubMed ID: 9179057)
1. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma.
Lazova R; Moynes R; May D; Scott G
Cancer; 1997 Jun; 79(11):2115-24. PubMed ID: 9179057
[TBL] [Abstract][Full Text] [Related]
2. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
[TBL] [Abstract][Full Text] [Related]
4. D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Bandarchi B; Ma L; Marginean C; Hafezi S; Zubovits J; Rasty G
Mod Pathol; 2010 Mar; 23(3):434-8. PubMed ID: 20062007
[TBL] [Abstract][Full Text] [Related]
5. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma.
Goldblum JR; Tuthill RJ
Am J Dermatopathol; 1997 Apr; 19(2):147-53. PubMed ID: 9129699
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Li N; McNiff J; Hui P; Manfioletti G; Tallini G
Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
[TBL] [Abstract][Full Text] [Related]
7. The Role of CD34 and D2-40 in the Differentiation of Dermatofibroma and Dermatofibrosarcoma Protuberans.
Sadullahoğlu C; Dere Y; Atasever TR; Öztop MT; Karaaslan Ö
Turk Patoloji Derg; 2017; 1(1):223-227. PubMed ID: 28832078
[TBL] [Abstract][Full Text] [Related]
8. Expression of the human progenitor cell antigen CD34 (HPCA-1) distinguishes dermatofibrosarcoma protuberans from fibrous histiocytoma in formalin-fixed, paraffin-embedded tissue.
Kutzner H
J Am Acad Dermatol; 1993 Apr; 28(4):613-7. PubMed ID: 7681857
[TBL] [Abstract][Full Text] [Related]
9. Reconsidering the diagnostic and prognostic utility of LN-2 for undifferentiated pleomorphic sarcoma and atypical fibroxanthoma.
Hollmig ST; Rieger KE; Henderson MT; West RB; Sundram UN
Am J Dermatopathol; 2013 Apr; 35(2):176-9. PubMed ID: 23000905
[TBL] [Abstract][Full Text] [Related]
10. Tenascin expression in cutaneous fibrohistiocytic tumors. Immunohistochemical investigation of 24 cases.
Franchi A; Santucci M
Am J Dermatopathol; 1996 Oct; 18(5):454-9. PubMed ID: 8902090
[TBL] [Abstract][Full Text] [Related]
11. When Immunohistochemistry Deceives Us: The Pitfalls of CD34 and Factor XIIIa Stains in Dermatofibroma and Dermatofibrosarcoma Protuberans.
John AM; Holahan HH; Singh P; Handler MZ; Lambert WC
Skinmed; 2017; 15(1):53-55. PubMed ID: 28270311
[No Abstract] [Full Text] [Related]
12. [Fibrohistiocytic skin tumors].
Hügel H
J Dtsch Dermatol Ges; 2006 Jul; 4(7):544-55. PubMed ID: 16827912
[TBL] [Abstract][Full Text] [Related]
13. [The ultrastructure of fibrous and histiocytic skin tumors (dermatofibroma, dermatofibrosarcoma protuberans, fibroxanthoma, and histiocytoma) (author's transl)].
Auböck L
Virchows Arch A Pathol Anat Histol; 1975 Oct; 368(3):253-74. PubMed ID: 171831
[TBL] [Abstract][Full Text] [Related]
14. Tenascin differentiates dermatofibroma from dermatofibrosarcoma protuberans: comparison with CD34 and factor XIIIa.
Kahn HJ; Fekete E; From L
Hum Pathol; 2001 Jan; 32(1):50-6. PubMed ID: 11172295
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous atypical fibrous histiocytoma.
Garrido-Ruiz MC; Ramos P; Enguita AB; Rodriguez Peralto JL
Am J Dermatopathol; 2009 Jul; 31(5):499-501. PubMed ID: 19542931
[TBL] [Abstract][Full Text] [Related]
16. Atrophic variants of dermatofibroma and dermatofibrosarcoma protuberans.
Zelger BW; Ofner D; Zelger BG
Histopathology; 1995 Jun; 26(6):519-27. PubMed ID: 7545142
[TBL] [Abstract][Full Text] [Related]
17. Fibrohistiocytic Tumors.
Romano RC; Fritchie KJ
Clin Lab Med; 2017 Sep; 37(3):603-631. PubMed ID: 28802503
[TBL] [Abstract][Full Text] [Related]
18. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans.
Abenoza P; Lillemoe T
Am J Dermatopathol; 1993 Oct; 15(5):429-34. PubMed ID: 7694515
[TBL] [Abstract][Full Text] [Related]
19. The value of immunohistochemistry in atypical cutaneous fibrous histiocytoma.
Wilk M; Zelger BG; Nilles M; Zelger B
Am J Dermatopathol; 2004 Oct; 26(5):367-71. PubMed ID: 15365367
[TBL] [Abstract][Full Text] [Related]
20. Neurofibromatous changes in dermatofibrosarcoma protuberans: a potential pitfall in the diagnosis of a serious cutaneous soft tissue neoplasm.
Kovarik CL; Hsu MY; Cockerell CJ
J Cutan Pathol; 2004 Aug; 31(7):492-6. PubMed ID: 15239679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
